CytomX Therapeutics, Inc. Contracts & Agreements
87 Contracts & Agreements
- Business Finance (15 contracts)
- Business Operations (17)
- Human Resources (39)
- Intellectual Property (5)
- Real Estate (2)
- Uncategorized (9)
- Amendment No. 3 to the Collaboration and License Agreement, dated as of May 18, 2023, by and between CytomX Therapeutics, Inc. and Amgen, Inc (Filed With SEC on August 8, 2023)
- Form of Amended and Restated Severance and Change of Control Agreement by and between CytomX Therapeutics, Inc. and each of its executive officers other than Sean A. McCarthy (Filed With SEC on August 8, 2023)
- Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Jeffrey Landau dated as of March 31, 2021 (Filed With SEC on August 8, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on July 3, 2023)
- Form of Tranche Warrant (Filed With SEC on July 3, 2023)
- Unit Purchase Agreement by and among the Company and the Purchasers, dated June 29, 2023 (Filed With SEC on July 3, 2023)
- Consulting Agreement effective as of October 1, 2022, by and between CytomX Therapeutics, Inc. and Carlos Campoy (Filed With SEC on November 8, 2022)
- Consulting Agreement effective as of September 13, 2022, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D (Filed With SEC on November 8, 2022)
- Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc. and Carlos Campoy (Filed With SEC on November 8, 2022)
- Separation Agreement effective as of September 12, 2022, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D (Filed With SEC on November 8, 2022)
- Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc. and Alison Hannah, M.D (Filed With SEC on November 8, 2022)
- Amendment No 3 to Collaboration and License Agreement, dated May 23, 2014, by and between the Company and Bristol Myers Squibb Company, effective as of October 11, 2022 (Filed With SEC on November 8, 2022)
- Form of 2015 Plan Restricted Share Unit Award Grant Notice and Agreement (Filed With SEC on March 1, 2022)
- Amendment No. 2 to the Collaboration and License Agreement, dated as of October 27, 2021, by and between CytomX Therapeutics, Inc. and Amgen, Inc (Filed With SEC on March 1, 2022)
- Amendment No 2 to Collaboration and License Agreement, as amended, dated March 17, 2017, by and between the Company and Bristol Myers Squibb, effective as of February 22, 2021 (Filed With SEC on May 6, 2021)
- Consulting Agreement, effective as of April 1, 2021, by and between CytomX Therapeutics, Inc. and Dr. Charles Fuchs (Filed With SEC on May 6, 2021)
- Consulting Agreement effective as of December 14, 2020, by and between CytomX Therapeutics, Inc and Dr. W. Michael Kavanaugh (Filed With SEC on February 24, 2021)
- Retirement Agreement by and between CytomX Therapeutics, Inc and Dr. W. Michael Kavanaugh, dated as of December 1, 2020 (Filed With SEC on February 24, 2021)
- Underwriting Agreement, dated as of January 20, 2021, among CytomX Therapeutics, Inc. and J.P Morgan securities LLC, Cowen and Company, LLC and Piper Sandler & Co., as... (Filed With SEC on January 25, 2021)
- Research Collaboration, Option and License Agreement dated as of May 30, 2013, by and between CytomX Therapeutics, Inc. and Pfizer, Inc (Filed With SEC on November 5, 2020)
- Collaboration and License Agreement dated as of May 23, 2014, by and between CytomX Therapeutics, Inc. and Bristol-Myers Squibb Company (Filed With SEC on November 5, 2020)
- Amendment No. 1 to the Collaboration and License Agreement, dated as of September 29, 2020, by and between CytomX Therapeutics, Inc. and Amgen, Inc (Filed With SEC on November 5, 2020)
- Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on August 6, 2020)
- Severance and Change of Control Agreement dated March 23, 2020, by and between CytomX Therapeutics, Inc. and Carlos Campoy (Filed With SEC on May 7, 2020)
- Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Carlos Campoy dated as of March 9, 2020 (Filed With SEC on May 7, 2020)
- Collaboration and License Agreement dated as of March 23, 2020, by and between CytomX Therapeutics, Inc. and Astellas Pharma Inc (Filed With SEC on May 7, 2020)
- Open Market Sale Agreement, dated as of February 27, 2020, by and between CytomX Therapeutics, Inc. and Jefferies LLC (Filed With SEC on February 27, 2020)
- Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 27, 2020)
- Severance and Change of Control Agreement effective as of February 3, 2020, by and between CytomX Therapeutics, Inc. and Alison Hannah, M.D (Filed With SEC on February 27, 2020)
- 2019 Employment Inducement Incentive Plan adopted on September 18, 2019 (2019 Plan) (Filed With SEC on November 7, 2019)
- Form of Stock Option Agreement under the 2019 Plan (Filed With SEC on November 7, 2019)
- Consulting Agreement effective as of August 19, 2019, by and between CytomX Therapeutics, Inc. and Rachel W. Humphrey, M.D (Filed With SEC on November 7, 2019)
- Separation Agreement effective as of September 5, 2019, by and between CytomX Therapeutics, Inc. and Rachel W. Humphrey, M.D (Filed With SEC on November 7, 2019)
- Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D. dated as of September 23, 2019 (Filed With SEC on November 7, 2019)
- Severance and Change of Control Agreement effective as of October 14, 2019, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D (Filed With SEC on November 7, 2019)
- Amended and Restated Discovery Collaboration and License Agreement, dated as of June 28, 2019, by and between CytomX Therapeutics, Inc., and AbbVie Ireland Unlimited Company (Filed With SEC on August 7, 2019)
- Amended and Restated Severance and Change of Control Agreement dated February 27, 2019, by and between CytomX Therapeutics, Inc. and Sean McCarthy. D. Phil (Filed With SEC on May 9, 2019)
- Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Lloyd Rowland (Filed With SEC on May 9, 2019)
- Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Rachel W. Humphrey, M.D (Filed With SEC on May 9, 2019)
- Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Michael Kavanaugh, M.D (Filed With SEC on May 9, 2019)
- Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Debanjan Ray (Filed With SEC on May 9, 2019)
- Amendment No.3 to Exclusive License Agreement effective as of April 2, 2019, by and between CytomX Therapeutics, Inc. and The Regents of the University of California (Filed With SEC on May 9, 2019)
- Consulting Agreement effective as of May 15, 2019, by and between CytomX Therapeutics, Inc. and Debanjan Ray (Filed With SEC on May 9, 2019)
- Consulting Agreement between CytomX Therapeutics, Inc and Dr. Hoyoung Huh, effective as of December 30, 2018 (Filed With SEC on February 27, 2019)
- First Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, dated as of October 5, 2016 (Filed With SEC on November 6, 2018)
- Second Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, dated as of March 31, 2017 (Filed With SEC on November 6, 2018)
- Third Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, dated as of January 3, 2018 (Filed With SEC on November 6, 2018)
- License Agreement by and between CytomX Therapeutics, Inc. and ImmunoGen Inc., dated as of February 12,2016 (Filed With SEC on November 6, 2018)
- Second Amendment to the Research Collaboration Agreement by and between CytomX Therapeutics, Inc. and ImmunoGen Inc., dated as of February 12,2016 (Filed With SEC on November 6, 2018)
- Third Amendment to the Research Collaboration Agreement by and between CytomX Therapeutics, Inc. and ImmunoGen Inc., dated as of March 3, 2017 (Filed With SEC on November 6, 2018)
- Severance and Change of Control Agreement, by and between CytomX Therapeutics, Inc. and Lloyd Rowland, dated as of May 16, 2018 (Filed With SEC on August 8, 2018)
- Underwriting Agreement, dated as of July 12, 2018, among CytomX Therapeutics, Inc. and Goldman Sachs & Co. LLC and Citigroup Global Markets Inc., as representatives of the... (Filed With SEC on July 17, 2018)
- Registration Rights Agreement dated as of September 29, 2017 by and between CytomX Therapeutics, Inc. and Amgen, Inc (Filed With SEC on November 7, 2017)
- Collaboration and License Agreement by and between CytomX Therapeutics, Inc. and Amgen, Inc. dated as of September 29, 2017 (Filed With SEC on November 7, 2017)
- SEPARATION AGREEMENT (Filed With SEC on August 7, 2017)
- [Signatures appear on the following page.] (Filed With SEC on August 7, 2017)
- AMENDMENT NUMER 1 TO EXTEND COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 5, 2017)
- [Signatures appear on the following page.] (Filed With SEC on March 2, 2017)
- [Signatures appear on the following page.] (Filed With SEC on March 2, 2017)
- [Signatures appear on the following page.] (Filed With SEC on March 2, 2017)
- [Signatures appear on the following page.] (Filed With SEC on May 6, 2016)
- FIRST AMENDMENT TO SEVERANCE AND CHANGE OF CONTROL AGREEMENT (Filed With SEC on March 7, 2016)
- THE COVE AT OYSTER POINT LEASE (Filed With SEC on December 16, 2015)
- CytomX Therapeutics, Inc. 2015 Equity Incentive Plan Option Award Notice (Filed With SEC on November 23, 2015)
- CytomX Therapeutics, Inc. 2015 Equity Incentive Plan Early Exercise Option Award Notice (Filed With SEC on November 23, 2015)
- CYTOMX THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN Adopted by Board: September 17, 2015 Approved by Stockholders: October 2, 2015 Termination Date: September 17, 2025 (Filed With SEC on October 6, 2015)
- CYTOMX THERAPEUTICS, INC. (aDelaware corporation) Shares of CommonStock UNDERWRITING AGREEMENT (Filed With SEC on September 28, 2015)
- CYTOMX THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN Adopted by Board: September 17, 2015 Termination Date: September 17, 2025 (Filed With SEC on September 28, 2015)
- CYTOMX THERAPEUTICS, INC. EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on September 28, 2015)
- SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (Filed With SEC on September 28, 2015)
- SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (Filed With SEC on September 11, 2015)
- AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on August 28, 2015)
- WARRANT TO PURCHASE PREFERRED STOCK (Filed With SEC on August 28, 2015)
- CYTOMX THERAPEUTICS, INC. 2011 STOCK INCENTIVE PLAN PREFACE (Filed With SEC on August 28, 2015)
- CYTOMX THERAPEUTICS, INC. 2011 STOCK INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT (Filed With SEC on August 28, 2015)
- 2010 STOCK INCENTIVE PLAN CYTOMX THERAPEUTICS, INC. a Delaware corporation September 21, 2010 2010 STOCK INCENTIVE PLAN (Filed With SEC on August 28, 2015)
- CYTOMX THERAPEUTICS, INC. STOCK OPTION AGREEMENT (2010 Stock Incentive Plan) (Filed With SEC on August 28, 2015)
- 460 WARD DRIVE, SUITE E1 SANTA BARBARA, CA 93111 TEL ###-###-#### FAX ###-###-#### WWW.CYTOMX.COM Revised December 15, 2010 (Filed With SEC on August 28, 2015)
- SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (Filed With SEC on August 28, 2015)
- INDEMNIFICATION AGREEMENT (Filed With SEC on August 28, 2015)
- RESEARCH COLLABORATION AGREEMENT BETWEEN CYTOMXTHERAPEUTICS, INC. AND IMMUNOGEN, INC. JANUARY 8, 2014 (Filed With SEC on August 28, 2015)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on August 28, 2015)
- RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT BY AND BETWEEN PFIZERINC. AND CYTOMX THERAPEUTICS, INC. MAY 30, 2013 (Filed With SEC on August 28, 2015)
- LEASE AGREEMENT (Filed With SEC on August 28, 2015)
- MASTER LOAN AND SECURITY AGREEMENT No. CYTOY Dated as ofDecember 20, 2013 (Filed With SEC on August 28, 2015)
- ATEL VENTURES, INC. MASTER LOAN AND SECURITY AGREEMENT NO. CYTOX Dated as of May 31, 2012 (Filed With SEC on August 28, 2015)
- AMENDMENT NO. 1 TO MASTER LOAN AND SECURITY AGREEMENT NO. CYTOX (Filed With SEC on August 28, 2015)